Previous reports have implicated both CB1 and CB2 receptors as potential targets for the development of IBD therapies [22,27,28,29,30] and ligands that bind to these receptors can relieve patients’ IBD symptoms [31]. Here, CNR1 is linked to inflammatory bowel disease.